Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

  • 1.

    SiegelRLMillerKDJemalA. Cancer statistics, 2017. CA Cancer J Clin2017;67:730.

  • 2.

    EhemanCHenleySJBallard-BarbashR. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer2012;118:23382366.

    • Search Google Scholar
    • Export Citation
  • 3.

    SimardEPWardEMSiegelRJemalA. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin2012;62:118128.

    • Search Google Scholar
    • Export Citation
  • 4.

    SmithBDSmithGLHurriaA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol2009;27:27582765.

    • Search Google Scholar
    • Export Citation
  • 5.

    StatBite. U.S. pancreatic cancer rates. J Natl Cancer Inst2010;102:1822.

  • 6.

    WorniMGullerUWhiteRR. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas2013;42:11571163.

    • Search Google Scholar
    • Export Citation
  • 7.

    ChariSTLeibsonCLRabeKG. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology2005;129:504511.

    • Search Google Scholar
    • Export Citation
  • 8.

    GuptaSVittinghoffEBertenthalD. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol2006;4:13661372; quiz 1301.

  • 9.

    RaghavanSRBallehaninnaUKChamberlainRS. The impact of perioperative blood glucose levels on pancreatic cancer prognosis and surgical outcomes: an evidence-based review. Pancreas2013;42:12101217.

    • Search Google Scholar
    • Export Citation
  • 10.

    CantoMIHarinckFHrubanRH. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut2013;62:339347.

    • Search Google Scholar
    • Export Citation
  • 11.

    CalleryMPChangKJFishmanEK. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol2009;16:17271733.

    • Search Google Scholar
    • Export Citation
  • 12.

    Al-HawaryMMFrancisIRChariST. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology2014;146:291304.e291.

    • Search Google Scholar
    • Export Citation
  • 13.

    HortonKMFishmanEK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am2002;40:12631272.

  • 14.

    HouseMGYeoCJCameronJL. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg2004;8:280288.

    • Search Google Scholar
    • Export Citation
  • 15.

    KlaussMSchobingerMWolfI. Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol2009;15:58275832.

    • Search Google Scholar
    • Export Citation
  • 16.

    McNultyNJFrancisIRPlattJF. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology2001;220:97102.

    • Search Google Scholar
    • Export Citation
  • 17.

    SchimaWBa-SsalamahAGoetzingerP. State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging2007;18:421429.

    • Search Google Scholar
    • Export Citation
  • 18.

    VachiranubhapBKimYHBalciNCSemelkaRC. Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging2009;20:39.

    • Search Google Scholar
    • Export Citation
  • 19.

    LiJHHeRLiYM. Endoscopic ultrasonography for tumor node staging and vascular invasion in pancreatic cancer: a meta-analysis. Dig Surg2014;31:297305.

    • Search Google Scholar
    • Export Citation
  • 20.

    AgarwalBAbu-HamdaEMolkeKL. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol2004;99:844850.

    • Search Google Scholar
    • Export Citation
  • 21.

    DeerenbergEBPoleyJWHermansJJ. Role of endoscopic ultrasonography in patients suspected of pancreatic cancer with negative helical MDCT scan. Dig Surg2011;28:398403.

    • Search Google Scholar
    • Export Citation
  • 22.

    NawazHFanCYKlokeJ. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP2013;14:484497.

    • Search Google Scholar
    • Export Citation
  • 23.

    WangWShpanerAKrishnaSG. Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT. Gastrointest Endosc2013;78:7380.

    • Search Google Scholar
    • Export Citation
  • 24.

    PaveyDAGressFG. The role of EUS-guided FNA for the evaluation of biliary strictures. Gastrointest Endosc2006;64:334337.

  • 25.

    DolejsSZarzaurBLZyromskiNJ. Does hyperbilirubinemia contribute to adverse patient outcomes following pancreatoduodenectomy?J Gastrointest Surg2017;21:647656.

    • Search Google Scholar
    • Export Citation
  • 26.

    MezhirJJBrennanMFBaserRE. A matched case-control study of preoperative biliary drainage in patients with pancreatic adenocarcinoma: routine drainage is not justified. J Gastrointest Surg2009;13:21632169.

    • Search Google Scholar
    • Export Citation
  • 27.

    van der GaagNARauwsEAvan EijckCH. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med2010;362:129137.

    • Search Google Scholar
    • Export Citation
  • 28.

    AhmedSIBochkarevVOleynikovDSassonAR. Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A2006;16:458463.

    • Search Google Scholar
    • Export Citation
  • 29.

    AllenVBGurusamyKSTakwoingiY. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev2013;11:CD009323.

    • Search Google Scholar
    • Export Citation
  • 30.

    WarshawALGuZYWittenbergJWaltmanAC. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg1990;125:230233.

    • Search Google Scholar
    • Export Citation
  • 31.

    BruggeWRDe WittJKlapmanJB. Techniques for cytologic sampling of pancreatic and bile duct lesions: the Papanicolaou Society of Cytopathology guidelines. Cytojournal2014;11(Suppl 1):2.

    • Search Google Scholar
    • Export Citation
  • 32.

    MicamesCJowellPSWhiteR. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc2003;58:690695.

    • Search Google Scholar
    • Export Citation
  • 33.

    OkashaHHNagaMIEsmatS. Endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasound-guided fine needle aspiration in diagnosis of focal pancreatic masses. Endosc Ultrasound2013;2:190193.

    • Search Google Scholar
    • Export Citation
  • 34.

    LayfieldLJDoddLFactorRSchmidtRL. Malignancy risk associated with diagnostic categories defined by the Papanicolaou Society of Cytopathology pancreaticobiliary guidelines. Cancer Cytopathol2014;122:420427.

    • Search Google Scholar
    • Export Citation
  • 35.

    HuangZLiuF. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol2014;35:74597465.

  • 36.

    BallehaninnaUKChamberlainRS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol2012;3:105119.

    • Search Google Scholar
    • Export Citation
  • 37.

    MannDVEdwardsRHoS. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol2000;26:474479.

    • Search Google Scholar
    • Export Citation
  • 38.

    MarrelliDCarusoSPedrazzaniC. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg2009;198:333339.

    • Search Google Scholar
    • Export Citation
  • 39.

    HartwigWStrobelOHinzU. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol2013;20:21882196.

    • Search Google Scholar
    • Export Citation
  • 40.

    KimYCKimHJParkJH. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?J Gastroenterol Hepatol2009;24:18691875.

    • Search Google Scholar
    • Export Citation
  • 41.

    KondoNMurakamiYUemuraK. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol2010;17:23212329.

    • Search Google Scholar
    • Export Citation
  • 42.

    BurrisHAIIIMooreMJAndersenJ. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol1997;15:24032413.

    • Search Google Scholar
    • Export Citation
  • 43.

    OettleHPostSNeuhausP. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA2007;297:267277.

    • Search Google Scholar
    • Export Citation
  • 44.

    OettleHNeuhausPHochhausA. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA2013;310:14731481.

    • Search Google Scholar
    • Export Citation
  • 45.

    GrunewaldRAbbruzzeseJLTarassoffPPlunkettW. Saturation of 2’,2’-difluorodeoxycytidine 5’-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol1991;27:258262.

    • Search Google Scholar
    • Export Citation
  • 46.

    PoplinEFengYBerlinJ. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol2009;27:37783785.

    • Search Google Scholar
    • Export Citation
  • 47.

    DemolsAPeetersMPolusM. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer2006;94:481485.

    • Search Google Scholar
    • Export Citation
  • 48.

    FineRLFogelmanDRSchreibmanSM. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol2008;61:167175.

    • Search Google Scholar
    • Export Citation
  • 49.

    CilibertoDBottaCCorrealeP. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer2013;49:593603.

    • Search Google Scholar
    • Export Citation
  • 50.

    SunCAnsariDAnderssonRWuDQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?World J Gastroenterol2012;18:49444958.

    • Search Google Scholar
    • Export Citation
  • 51.

    HeinemannVBoeckSHinkeA. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer2008;8:82.

    • Search Google Scholar
    • Export Citation
  • 52.

    HeinemannVQuietzschDGieselerF. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol2006;24:39463952.

    • Search Google Scholar
    • Export Citation
  • 53.

    HerrmannRBodokyGRuhstallerT. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol2007;25:22122217.

    • Search Google Scholar
    • Export Citation
  • 54.

    Von HoffDDRamanathanRKBoradMJ. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol2011;29:45484554.

    • Search Google Scholar
    • Export Citation
  • 55.

    Von HoffDDErvinTArenaFP. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med2013;369:16911703.

    • Search Google Scholar
    • Export Citation
  • 56.

    ChioreanEGVon HoffDDReniM. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol2016;27:654660.

    • Search Google Scholar
    • Export Citation
  • 57.

    GoldsteinDVon HoffDDMooreM. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT). Eur J Cancer2016;52:8591.

    • Search Google Scholar
    • Export Citation
  • 58.

    GoldsteinDEl-MaraghiRHHammelP. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst2015;107:pii: dju413.

    • Search Google Scholar
    • Export Citation
  • 59.

    BuccheriGFerrignoDTamburiniM. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer1996;32a:11351141.

    • Search Google Scholar
    • Export Citation
  • 60.

    MaCBandukwalaSBurmanD. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer2010;46:31753183.

    • Search Google Scholar
    • Export Citation
  • 61.

    MooreMJGoldsteinDHammJ. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:19601966.

    • Search Google Scholar
    • Export Citation
  • 62.

    ColucciGGiulianiFGebbiaV. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer2002;94:902910.

    • Search Google Scholar
    • Export Citation
  • 63.

    ColucciGLabiancaRDi CostanzoF. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol2010;28:16451651.

    • Search Google Scholar
    • Export Citation
  • 64.

    GolanTKanjiZSEpelbaumR. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer2014;111:11321138.

    • Search Google Scholar
    • Export Citation
  • 65.

    MajdakEJDebniakJMilczekT. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer2005;104:10041012.

    • Search Google Scholar
    • Export Citation
  • 66.

    StefanssonOAJonassonJGJohannssonOT. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res2009;11:R47.

    • Search Google Scholar
    • Export Citation
  • 67.

    FerroneCRLevineDATangLH. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol2009;27:433438.

  • 68.

    OliverGRSugarELaheruDDiazLA. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January22–242010; Orlando, FL. Abstract 180.

    • Search Google Scholar
    • Export Citation
  • 69.

    CunninghamDChauIStockenDD. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol2009;27:55135518.

    • Search Google Scholar
    • Export Citation
  • 70.

    LiQYanHLiuW. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One2014;9:e104346.

    • Search Google Scholar
    • Export Citation
  • 71.

    ConroyTDesseigneFYchouM. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med2011;364:18171825.

  • 72.

    PeixotoRDHoMRenoufDJ. Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncolin press.

    • Search Google Scholar
    • Export Citation
  • 73.

    ConroyTPaillotBFrancoisE. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol2005;23:12281236.

    • Search Google Scholar
    • Export Citation
  • 74.

    YchouMDesseigneFGuimbaudR. Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial [abstract]. J Clin Oncol2007;25(Suppl):Abstract 4516.

    • Search Google Scholar
    • Export Citation
  • 75.

    Gourgou-BourgadeSBascoul-MolleviCDesseigneF. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol2013;31:2329.

    • Search Google Scholar
    • Export Citation
  • 76.

    LoweryMAYuKHAdelNG. Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC) [abstract]. J Clin Oncol2012;30(Suppl):Abstract 4057.

    • Search Google Scholar
    • Export Citation
  • 77.

    SteinSMJamesESDengY. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer2016;114:809812.

    • Search Google Scholar
    • Export Citation
  • 78.

    BoeckSVehling-KaiserUWaldschmidtD. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anticancer Drugs2010;21:94100.

    • Search Google Scholar
    • Export Citation
  • 79.

    CartwrightTHCohnAVarkeyJA. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol2002;20:160164.

    • Search Google Scholar
    • Export Citation
  • 80.

    PelzerUSchwanerIStielerJ. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer2011;47:16761681.

    • Search Google Scholar
    • Export Citation
  • 81.

    XiongHQVaradhacharyGRBlaisJC. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer2008;113:20462052.

    • Search Google Scholar
    • Export Citation
  • 82.

    RahmaOEDuffyALiewehrDJ. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol2013;24:19721979.

    • Search Google Scholar
    • Export Citation
  • 83.

    MaiseyNChauICunninghamD. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol2002;20:31303136.

    • Search Google Scholar
    • Export Citation
  • 84.

    ChioreanEGVon HoffDDTaberneroJ. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer2016;115:e13.

    • Search Google Scholar
    • Export Citation
  • 85.

    PelzerUKubicaKStielerJ. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study [abstract]. J Clin Oncol2008;26(Suppl):Abstract 4508.

    • Search Google Scholar
    • Export Citation
  • 86.

    SaifMW. New developments in the treatment of pancreatic cancer. Highlights from the “44th ASCO Annual Meeting”. Chicago, IL, USA. May 30 - June 3, 2008. JOP2008;9:391397.

    • Search Google Scholar
    • Export Citation
  • 87.

    OettleHRiessHStielerJM. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol2014;32:24232429.

    • Search Google Scholar
    • Export Citation
  • 88.

    GillSKoYJCrippsC. PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy[published online ahead of print September 12 2016]. J Clin Oncolin press.

    • Search Google Scholar
    • Export Citation
  • 89.

    UccelloMMoschettaMArkenauHT. Second-line combination therapies in pancreatic cancer: where are we now?J Clin Oncol2017;35:13701371.

  • 90.

    Wang-GillamALiCPBodokyG. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet2016;387:545557.

    • Search Google Scholar
    • Export Citation
  • 91.

    Wang-GillamALiCPBodokyG. Updated overall survival (OS) analysis of NAPOLI-1: phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy [abstract]. J Clin Oncol2016;34(Suppl):Abstract 4126.

    • Search Google Scholar
    • Export Citation
  • 92.

    NeoptolemosJPStockenDDFriessH. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med2004;350:12001210.

    • Search Google Scholar
    • Export Citation
  • 93.

    CraneCHBen-JosefESmallW. Chemotherapy for pancreatic cancer. N Engl J Med2004;350:27132715.

  • 94.

    KoshyMCLandryJCCavanaughSX. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys2005;61:965966.

  • 95.

    MorrisSLBeasleyMLeslieM. Chemotherapy for pancreatic cancer. N Engl J Med2004;350:27132715; author reply 2713–2715.

  • 96.

    RenFXuYCWangHX. Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop?Pancreatology2012;12:162169.

    • Search Google Scholar
    • Export Citation
  • 97.

    LiaoWCChienKLLinYL. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol2013;14:10951103.

    • Search Google Scholar
    • Export Citation
  • 98.

    KoobyDAGillespieTWLiuY. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the National Cancer Data Base. Ann Surg Oncol2013;20:36343642.

    • Search Google Scholar
    • Export Citation
  • 99.

    MorgantiAGFalconiMvan StiphoutRG. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys2014;90:911917.

    • Search Google Scholar
    • Export Citation
  • 100.

    NeoptolemosJPStockenDDDunnJA. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg2001;234:758768.

    • Search Google Scholar
    • Export Citation
  • 101.

    CorsiniMMMillerRCHaddockMG. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol2008;26:35113516.

    • Search Google Scholar
    • Export Citation
  • 102.

    HsuCCHermanJMCorsiniMM. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol2010;17:981990.

    • Search Google Scholar
    • Export Citation
  • 103.

    ButturiniGStockenDDWenteMN. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg2008;143:7583; discussion 83.

    • Search Google Scholar
    • Export Citation
  • 104.

    CraneCHAbbruzzeseJLEvansDB. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?Int J Radiat Oncol Biol Phys2002;52:12931302.

    • Search Google Scholar
    • Export Citation
  • 105.

    HuangJRobertsonJMMargolisJ. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol2011;99:114119.

    • Search Google Scholar
    • Export Citation
  • 106.

    MurphyJDAdusumilliSGriffithKA. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys2007;68:801808.

    • Search Google Scholar
    • Export Citation
  • 107.

    ZhuCPShiJChenYX. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol2011;99:108113.

    • Search Google Scholar
    • Export Citation
  • 108.

    MukherjeeSHurtCNBridgewaterJ. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol2013;14:317326.

    • Search Google Scholar
    • Export Citation
  • 109.

    HurtCNMukherjeeSBridgewaterJ. Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys2015;93:810818.

    • Search Google Scholar
    • Export Citation
  • 110.

    LoehrerPJSrFengYCardenesH. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol2011;29:41054112.

    • Search Google Scholar
    • Export Citation
  • 111.

    PhilipPA. Locally advanced pancreatic cancer: where should we go from here?J Clin Oncol2011;29:40664068.

  • 112.

    ChauffertBMornexFBonnetainF. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol2008;19:15921599.

    • Search Google Scholar
    • Export Citation
  • 113.

    BlackstockAWTepperJENiedwieckiD. Cancer and Leukemia Group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer2003;34:107116.

    • Search Google Scholar
    • Export Citation
  • 114.

    HuguetFAndreTHammelP. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol2007;25:326331.

    • Search Google Scholar
    • Export Citation
  • 115.

    HuguetFGirardNGuercheCS. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol2009;27:22692277.

    • Search Google Scholar
    • Export Citation
  • 116.

    KrishnanSRanaVJanjanNA. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer2007;110:4755.

    • Search Google Scholar
    • Export Citation
  • 117.

    HammelPHuguetFvan LaethemJL. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA2016;315:18441853.

    • Search Google Scholar
    • Export Citation
  • 118.

    HermanJMChangDTGoodmanKA. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer2015;121:11281137.

    • Search Google Scholar
    • Export Citation
  • 119.

    SchellenbergDKimJChristman-SkiellerC. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys2011;81:181188.

    • Search Google Scholar
    • Export Citation
  • 120.

    LiDXieKWolffRAbbruzzeseJL. Pancreatic cancer. Lancet2004;363:10491057.

  • 121.

    NeoptolemosJPStockenDDBassiC. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA2010;304:10731081.

    • Search Google Scholar
    • Export Citation
  • 122.

    RegineWFWinterKAAbramsRA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA2008;299:10191026.

    • Search Google Scholar
    • Export Citation
  • 123.

    NeoptolemosJPPalmerDHGhanehP. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet2017;389:10111024.

    • Search Google Scholar
    • Export Citation
  • 124.

    AllisonDCPiantadosiSHrubanRH. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol1998;67:151159.

    • Search Google Scholar
    • Export Citation
  • 125.

    HowardTJKrugJEYuJ. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg2006;10:13381345.

    • Search Google Scholar
    • Export Citation
  • 126.

    SohnTAYeoCJCameronJL. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg2000;4:567579.

    • Search Google Scholar
    • Export Citation
  • 127.

    AbramsRALowyAMO'ReillyEM. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol2009;16:17511756.

    • Search Google Scholar
    • Export Citation
  • 128.

    KatzMHMarshRHermanJM. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol2013;20:27872795.

    • Search Google Scholar
    • Export Citation
  • 129.

    TalamontiM. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol2006;13:10191020.

  • 130.

    VaradhacharyGRTammEPAbbruzzeseJL. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol2006;13:10351046.

    • Search Google Scholar
    • Export Citation
  • 131.

    GumbsAARodriguez RiveraAM. Laparoscopic pancreatoduodenectomy: a review of 285 published cases. Ann Surg Oncol2011;18:13351341.

  • 132.

    VenkatREdilBHSchulickRD. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg2012;255:10481059.

    • Search Google Scholar
    • Export Citation
  • 133.

    ShrikhandeSVBarretoSG. Extended pancreatic resections and lymphadenectomy: an appraisal of the current evidence. World J Gastrointest Surg2010;2:3946.

    • Search Google Scholar
    • Export Citation
  • 134.

    CorderaFArcieroCALiT. Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma. Ann Surg Oncol2007;14:23302336.

    • Search Google Scholar
    • Export Citation
  • 135.

    ShimadaKSakamotoYSanoTKosugeT. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J Am Coll Surg2006;203:345352.

    • Search Google Scholar
    • Export Citation
  • 136.

    GundrySRStrodelWEKnolJA. Efficacy of preoperative biliary tract decompression in patients with obstructive jaundice. Arch Surg1984;119:703708.

    • Search Google Scholar
    • Export Citation
  • 137.

    HatfieldARTobiasRTerblancheJ. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet1982;2:896899.

    • Search Google Scholar
    • Export Citation
  • 138.

    HeslinMJBrooksADHochwaldSN. A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy. Arch Surg1998;133:149154.

    • Search Google Scholar
    • Export Citation
  • 139.

    LaiECMokFPFanST. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg1994;81:11951198.

  • 140.

    McPhersonGABenjaminISHodgsonHJ. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Br J Surg1984;71:371375.

    • Search Google Scholar
    • Export Citation
  • 141.

    PittHAGomesASLoisJF. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?Ann Surg1985;201:545553.

    • Search Google Scholar
    • Export Citation
  • 142.

    ThomasJHConnorCSPierceGE. Effect of biliary decompression on morbidity and mortality of pancreatoduodenectomy. Am J Surg1984;148:727-731.

    • Search Google Scholar
    • Export Citation
  • 143.

    AadamAAEvansDBKhanA. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc2012;76:6775.

    • Search Google Scholar
    • Export Citation
  • 144.

    MullenJTLeeJHGomezHF. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg2005;9:10941104; discussion 1104–1095.

    • Search Google Scholar
    • Export Citation
  • 145.

    VaradhacharyGRWolffRACraneCH. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol2008;26:34873495.

    • Search Google Scholar
    • Export Citation
  • 146.

    VaradhacharyGRWolffRA. The war on pancreatic cancer: are we gaining ground?Oncology2011;24:13351336.

  • 147.

    SinnMLierschTGellertK. CONKO-005: adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—a prospective randomized phase III study [abstract]. J Clin Oncol2015;33(Suppl):Abstract 4007.

    • Search Google Scholar
    • Export Citation
  • 148.

    EsnaolaNFChaudharyUBO'BrienP. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys2014;88:837844.

    • Search Google Scholar
    • Export Citation
  • 149.

    FestaVAndriulliAValvanoMR. Neoadjuvant chemoradiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP2013;14:618625.

    • Search Google Scholar
    • Export Citation
  • 150.

    KimEJBen-JosefEHermanJM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer2013;119:26922700.

    • Search Google Scholar
    • Export Citation
  • 151.

    LandryJCatalanoPJStaleyC. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol2010;101:587592.

    • Search Google Scholar
    • Export Citation
  • 152.

    MartiJLHochsterHSHiotisSP. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol2008;15:35213531.

    • Search Google Scholar
    • Export Citation
  • 153.

    Van BurenG2ndRamanathanRKKrasinskasAM. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol2013;20:37873793.

    • Search Google Scholar
    • Export Citation
  • 154.

    KatzMHShiQAhmadSA. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg2016:e161137.

    • Search Google Scholar
    • Export Citation
  • 155.

    KatzMHCraneCHVaradhacharyG. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol2014;24:105112.

  • 156.

    ArtinyanAAnayaDAMcKenzieS. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer2011;117:20442049.

    • Search Google Scholar
    • Export Citation
  • 157.

    BreslinTMHessKRHarbisonDB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol2001;8:123132.

    • Search Google Scholar
    • Export Citation
  • 158.

    EvansDBRichTAByrdDR. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg1992;127:13351339.

    • Search Google Scholar
    • Export Citation
  • 159.

    EvansDBVaradhacharyGRCraneCH. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol2008;26:34963502.

    • Search Google Scholar
    • Export Citation
  • 160.

    HoffmanJPWeeseJLSolinLJ. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg1995;169:7177.

    • Search Google Scholar
    • Export Citation
  • 161.

    HoffmanJPLipsitzSPisanskyT. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol1998;16:317323.

    • Search Google Scholar
    • Export Citation
  • 162.

    MornexFGirardNDelperoJRPartenskyC. Radiochemotherapy in the management of pancreatic cancer-part I: neoadjuvant treatment. Semin Radiat Oncol2005;15:226234.

    • Search Google Scholar
    • Export Citation
  • 163.

    PalmerDHStockenDDHewittH. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol2007;14:20882096.

    • Search Google Scholar
    • Export Citation
  • 164.

    QuirosRMBrownKMHoffmanJP. Neoadjuvant therapy in pancreatic cancer. Cancer Invest2007;25:267273.

  • 165.

    SpitzFRAbbruzzeseJLLeeJE. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol1997;15:928937.

    • Search Google Scholar
    • Export Citation
  • 166.

    TalamontiMSSmallWMulcahyMF. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol2006;13:150158.

    • Search Google Scholar
    • Export Citation
  • 167.

    PingpankJFHoffmanJPRossEA. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg2001;5:121130.

    • Search Google Scholar
    • Export Citation
  • 168.

    TachezyMGebauerFPetersenC. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer2014;14:411.

    • Search Google Scholar
    • Export Citation
  • 169.

    ReniM. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?World J Gastroenterol2010;16:48834887.

  • 170.

    WhiteRRHurwitzHIMorseMA. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol2001;8:758765.

  • 171.

    FurmanMJLambertLASullivanMEWhalenGF. Rational follow-up after curative cancer resection. J Clin Oncol2013;31:11301133.

  • 172.

    TzengCWFlemingJBLeeJE. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford)2012;14:365372.

    • Search Google Scholar
    • Export Citation
  • 173.

    TzengCWAbbottDECantorSB. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol2013;20:21972203.

    • Search Google Scholar
    • Export Citation
  • 174.

    PhilipPAMooneyMJaffeD. Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on pancreas cancer treatment. J Clin Oncol2009;27:56605669.

    • Search Google Scholar
    • Export Citation
  • 175.

    TemperoMABerlinJDucreuxM. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol2011;22:15001506.

    • Search Google Scholar
    • Export Citation
  • 176.

    TemperoMAKlimstraDBerlinJ. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res2013;19:538540.

    • Search Google Scholar
    • Export Citation
  • 177.

    EllisLMBernsteinDSVoestEE. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol2014;32:12771280.

    • Search Google Scholar
    • Export Citation
  • 178.

    BaoZCaoCGengX. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis. Oncotarget2016;7:76297639.

    • Search Google Scholar
    • Export Citation
  • 179.

    KaufmanBShapira-FrommerRSchmutzlerRK. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol2015;33:244250.

    • Search Google Scholar
    • Export Citation
  • 180.

    DomchekSMHendifarAEMcWilliamsRR. RUCAPANC: an open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation [abstract]. J Clin Oncol2016;34(Suppl):Abstract 4110.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 1 0
Full Text Views 4541 4541 498
PDF Downloads 1498 1498 143
EPUB Downloads 0 0 0